KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Enterprise Value (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Enterprise Value for 11 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 3.78% to -$2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 billion through Dec 2025, down 3.78% year-over-year, with the annual reading at -$2.0 billion for FY2025, 3.78% down from the prior year.
  • Enterprise Value hit -$2.0 billion in Q4 2025 for CRISPR Therapeutics AG, down from -$1.9 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.7 billion in Q4 2023 to a low of -$2.6 billion in Q2 2021.
  • Historically, Enterprise Value has averaged -$2.0 billion across 5 years, with a median of -$1.9 billion in 2024.
  • Biggest five-year swings in Enterprise Value: tumbled 174.0% in 2021 and later grew 23.7% in 2022.
  • Year by year, Enterprise Value stood at -$2.4 billion in 2021, then grew by 23.7% to -$1.8 billion in 2022, then increased by 6.7% to -$1.7 billion in 2023, then decreased by 12.41% to -$1.9 billion in 2024, then decreased by 3.78% to -$2.0 billion in 2025.
  • Business Quant data shows Enterprise Value for CRSP at -$2.0 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.7 billion in Q2 2025.